The present invention is directed to esters of (+)-.alpha.-(2,3 Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol, pharmaceutical formulations, methods of making and methods of using these esters. These compounds antagonize the effects of serotonin at the 5HT.sub.2A receptor and are useful in treating various conditions such as, for example, psychoses such as schizophrenia.
The present invention is directed to use of (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidin- emethanol or its prodrug depicted as Formula II, wherein R is C.sub.1-20alkyl, in treating patients for behavioral or psychological symptoms associated with Alzheimer's disease, Lewy body dementia or Parkinson's disease. ##STR00001##